Stata DX develops a mobile, cloud-connected platform for point-of-care neurological diagnostics using minimal whole blood samples. This system supports multiplexed cartridges capable of running immunoassays and other detection methods for multiple biomarkers simultaneously. The technology enables multi-biomarker guided disease management strategies directly in the clinic or patient home.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current neurological assessments often rely on specialized equipment and laboratory analysis, creating delays in diagnosis and limiting accessibility for point-of-care or in-home settings. The need for rapid, convenient, and comprehensive biomarker analysis in neurology remains unmet.
Solution
StataDX is developing a point-of-care diagnostics platform for neurology that enables real-time disease management in both clinical and home environments. The platform utilizes multiplexed cartridges to analyze up to six biomarkers from a small fingerprick blood sample (30 µL). This approach facilitates the implementation of multi-biomarker guided disease management strategies, providing immediate insights for timely intervention. The system supports immunoassays, enzymatic assays, and nucleic acid detection, offering a versatile solution for a wide range of neurological conditions.
Target Audience
The primary target audience includes neurologists, clinical researchers, and healthcare providers seeking rapid and accessible point-of-care diagnostic solutions for neurological diseases, as well as pharmaceutical companies conducting clinical studies.
Features
- Multiplexed cartridges capable of analyzing up to six biomarkers per cartridge
- Wide assay menu supporting immunoassays, enzymatic assays, and nucleic acid detection
- Mobile and cloud-connected platform for 24/7 accessibility and data management
- Fingerprick whole blood sample requirement (30 µL) for ease of use
- Validated analytes for reliable and accurate results
- Potential application in clinical studies for biomarker analysis